
Bipolar Dashboard

February 2001

The Lilly logo is written in a black, cursive script font.

Answers That Matter.



Dashboard

Bipolar diagnosis codes (ICD-10)

F30.0 Hypomania

F30.1 - Mania without psychotic symptoms

F30.2 - Mania with psychotic symptoms

F30.8 - Other manic episodes

F30.9 - Manic episode unspecified

F31.0 - Bipolar affective disorder, hypomanic

F31.1 - Bipolar affective disorder, manic

F31.2 - Bipolar affective disorder, manic and psychotic

F31.3 - Bipolar affective disorder, mild/moderate depression

F31.4 - Bipolar affective disorder, severe depression

F31.5 - Bipolar affective disorder, severe depression and psychoses

F31.6 - Bipolar affective disorder, mixed

F31.7 - Bipolar affective disorder, in remission

F31.8 - Other bipolar affective disorder

F31.9 - Bipolar affective disorder, unspecified

F34.0 - Cyclothymia


Company Confidential
Copyright © 2000 Eli Lilly and Company

Redacted

Redacted

Redacted

Redacted



Redacted


Redacted

Redacted


Redacted

Redacted

Redacted



Redacted



Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

ZY 8418 1214

Redacted

Redacted

Redacted



STATISTICAL ANALYSIS OF PRODUCTS BY ATTRIBUTES: OLANZAPINE - USA

KEY THERAPY DRIVERS

	Olanzapine	Lithium	Valproate	Carbamazepine	Topiramate	Haloperidol	Risperidone
Effect on mood/affective symptoms	4.88	5.87	5.92	4.98	4.18	2.94	4.13
Stabilization of mood	4.85	6.21	6.19	5.46	4.27	3.44	3.98
Patient acceptability is good	5.31	4.79	5.36	4.73	4.34	3.32	5.27
Patient responded previously	5.57	5.69	5.64	5.38	4.28	5.01	5.52
Favourable benefit risk profile	5.24	4.24	5.01	4.12	4.37	3.16	5.15
Reduce frequency of depressive episodes	3.25	4.89	4.62	4.00	3.03	2.19	2.76
Improves quality of life	5.19	5.33	5.50	4.85	4.17	3.76	4.94
Reduce severity of depressive episodes	3.55	4.70	4.33	3.80	3.17	2.22	2.93
Fast onset of action	4.87	3.81	4.51	3.76	3.41	5.44	4.86
Reduce aggression/irritability	5.55	5.06	5.43	4.89	3.90	5.47	5.33

PRODUCT WEAKNESSES

Reduced risk of weight gain	2.08	2.98	3.14	3.96	4.92	3.21	3.74
Avoids sedation	3.19	4.67	3.99	3.98	4.12	3.47	4.30
Reduce frequency of depressive episodes	3.25	4.89	4.62	4.00	3.03	2.19	2.76
Value for money	3.31	5.98	4.67	4.44	3.12	5.25	3.52
Reduce severity of depressive episodes	3.55	4.70	4.33	3.80	3.17	2.22	2.93

-  Control is observed to "win" on attribute
-  Competitor product is observed to "win" on attribute
- A significant difference is observed, however the attribute does not necessarily indicate "winners" & "losers"*

Company Confidential
Copyright © 2000 Eli Lilly and Company

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted

Redacted